Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SOM Biotech

Request full access

Biopharmaceutical company focused on the accelerated development of drugs for orphan indications through AI technology

Montcada i Reixac, SpainFounded 2009Biotech & Life Sciences

About SOM Biotech

SOM Biotech is a clinical-stage biopharmaceutical company that leverages Artificial Intelligence (AI) to accelerate the discovery of therapies for unmet medical needs. The company operates in the healthcare and pharmaceutical sectors, focusing on developing treatments for rare and orphan diseases. SOM Biotech's business model revolves around using its proprietary AI-based drug discovery technology to identify and develop new therapeutic solutions more efficiently than traditional methods. This approach reduces the time and cost associated with research and development (R&D) processes. The company generates revenue through partnerships, licensing agreements, and the commercialization of its drug candidates. Key clients include pharmaceutical companies, healthcare providers, and research institutions. SOM Biotech has achieved significant milestones, such as positive Phase 2a clinical data for its drug candidate SOM3355 and receiving Orphan Drug Designation from the FDA. The company continues to innovate and expand its pipeline, aiming to bring effective treatments to patients faster.

Source: Dealroom company data

At a glance

Status
Operational
Employees
14
Open positions
None listed
Dealroom signal
75.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Neurology, Core AI, Spinout, Tech for Biotech and Pharma, AI Drug Discovery
Technology
Artificial Intelligence, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing Jan 2021 $0 — Monte Carlo Capital —
EARLY VC✓Equity / VC Mar 2019 $7.7M $220M Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

SOM Biotech website traffic

Latest recorded traffic for SOM Biotech is 2K monthly website visits, up 53.8% over the last three months. SOM Biotech's team grew 7.7% over the past year.

Latest monthly visits2K 3-month web change+53.8% 1-year team growth+7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SOM Biotech in the Montcada i Reixac ecosystem

Live from Dealroom

The SOM Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Monte Carlo Capital

Other known investors3 additional known investors

  • Biomedical Research Institute of Lleida
  • Universitat de Lleida
  • HTH
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See SOM Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.